期刊文献+

异帕米星与替加环素联合治疗多重耐药鲍曼不动杆菌肺炎的临床观察 被引量:10

Clinical Observation of Isepamicin and Tigecycline Combined Treatment of Multi Drug Resistant Acinetobacter Pneumonia Bauman
下载PDF
导出
摘要 目的探究异帕米星联合替加环素治疗多重耐药鲍曼不动杆菌肺炎的临床疗效。方法选取多重耐药鲍曼不动杆菌肺炎患者88例,随机分为对照组和治疗组各44例,对照组采用头孢哌酮舒巴坦治疗,治疗组采用异帕米星联合替加环素治疗。结果治疗组患者治疗有效率和细菌清除率高于对照组(P<0.05)。结论采用异帕米星联合替加环素治疗多重耐药鲍曼不动杆菌肺炎,疗效显著。 Objective Exploration of isepamicin joint ring for additional clinical efficacy in treatment of multi drug resistant Acinetobacter pneumonia Bauman. Methods Select the multidrug resistance of Bauman stil for 88 patients with Bacil us pneumonia, were randomly divided into control group and treatment group with 44 cases in each group, the control group used cefoperazone sulbactam in the treatment, the treatment group used isepamicin combined with tigecycline treatment. Results The treatment effective rate and bacterial clearance rate were higher than the control group (P〈0.05). Conclusion Using isepamicin combined with tigecycline treatment of multidrug resistant Bauman Acinetobacter pneumonia,the curative effect is remarkable.
作者 滕晓泉
出处 《中国卫生标准管理》 2015年第4期122-123,共2页 China Health Standard Management
关键词 异帕米星 替加环素 临床疗效 Isepamicin Tigecycline Clinical curative effect
  • 相关文献

参考文献3

二级参考文献55

  • 1叶惠芬,陈惠玲,周小棉,张晓洁.广州地区鲍曼不动杆菌产β内酰胺酶基因型调查[J].中国感染与化疗杂志,2008,8(4):307-310. 被引量:8
  • 2王辉,郭萍,孙宏莉,杨启文,陈民钧,朱元珏,徐英春,谢秀丽.碳青霉烯类耐药的不动杆菌分子流行病学及其泛耐药的分子机制[J].中华检验医学杂志,2006,29(12):1066-1073. 被引量:237
  • 3Wilcox M, Nathwani D, Dryden M. Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections [ J ]. J Antimicrob Chemother, 2004,53 : 335-344.
  • 4Moise PA, Forrest A, Birmingham MC, et al. The efficacy and safety of linezolid as treatment for Staphylococcus aureus infectionsin compassionate use patients who are intolerant of, or who have failed to respond to, vancomycin [ J ]. J Antimicrob Chemother, 2002,50 : 1017-1026.
  • 5Neonakis IK, Spandidos DA, Petinaki E. Confronting muhidrug- resistant Acinetobacter baumanii : a review [ J ]. Int J Antimicrob Agents,2011,37:102-109.
  • 6Hern&ndez-Torres A, Garcia-V:izquez E, G6mez J, et al. Carbapenem and multidrug-resistant Acinetobacter baumannii colonisation/infection: epidemiology and factors associated with infection[ J]. Med Clin (Barc) ,2010,135:389-396.
  • 7Peleg AY,Seifert H,Paterson DL,et al.Acinetobacterbaumannii:emergence of a successful pathogen[J].Clinical microbiology reviews,2008,21(3):538-582.
  • 8Chin BS,Han SH,Choi SH,et al.The characteristics of metallo-β-lactamase-producing gramnegative bacilli isolated from sputum and urine:a single center experience in Korea[J].Yonsei Med J,2011,52(2):351-357.
  • 9Poulakou G,Kontopidou FV,Paramythiotou E,et al.Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens[J].J Infect,2009,58(4):273-284.
  • 10Scheetz MH,Qi C,Warren JR,et al.In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or resistant Acinetobacterbaumannii[J].Antimicrobial Agents Chemother,2007,51(5):1621-1626.

共引文献39

同被引文献112

  • 1王微,华春珍.替加环素联合异帕米星治疗多重耐药鲍曼不动杆菌肺炎的疗效观察[J].中国生化药物杂志,2014,34(4):1-3. 被引量:13
  • 2刘莲凤,叶瑞梅,刘旗明.老年无多重耐药危险医院获得性肺炎患者病原菌分布及耐药性分析[J].中国老年学杂志,2015,35(2):331-333. 被引量:11
  • 3任建安,黎介寿.严重腹腔感染的综合治疗[J].中国实用外科杂志,2007,27(12):940-942. 被引量:51
  • 4Garnacho-Montero J, Amaya-Villar R. Multiresistant Acinetobacter baumannii infections: epidemiology and management[J]. Curt Opin Infect Dis, 2010, 23(4): 332-339.
  • 5Karageorgopoulos D E, Falagas M E. Current control and treatment of multidrug-resistant Acinetobacter baumannii infections[J]. Lancet Infect Dis, 2008, 8(12): 751-762.
  • 6Wang L F, Li J L, Ma W H, et al. Drug resistance analysis of bacterial strains isolated from burn patients[J]. Gen Mol Res Gmr, 2014, 13(4): 9727-9734.
  • 7Chopra T, Marchaim D, Awali R A, et al. Epidemiology of bloodstream infections caused by Acinetobacter baumannii and impact of drug resistance to both carbapenems and ampicillin-sulbactam on clinical outcomes[J]. Antimicrob Agents Chemother, 2013, 57(12): 6270-6275.
  • 8Rose W E, Rybak M J. Tigecycline: first of a new class of antimicrobial agents[J]. Pharmacotherapy, 2006, 26(8): 1099-1110.
  • 9Karageorgopoulos D E, Kelesidis T, Kelesidis I, et al Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infectionsa review of the scientific evidence[J]. J Antimicrob Chemother, 2008, 62(I): 45-55.
  • 10Guner R, Hasanoglu I, Keske S, et al. Outcomes in patients infected with carbapenem-resistant Acinetobacter baumannii and treated with tigecycline alone or in combination therapy[J]. Infection, 2011, 39(6): 515-518.

引证文献10

二级引证文献71

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部